Barbara P. Willekens

Antwerpen, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Causal effects of multiple sclerosis therapies in left-truncated registry data.

Journal: Multiple sclerosis (Houndmills, Basingstoke, England)

Published: July 21, 2026

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Corrigendum to "Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study" [Multiple Sclerosis and Related Disorders Vol 106; Feb 2026; Article Number 106885].

Journal: Multiple sclerosis and related disorders

Published: April 10, 2026

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Treatment escalation after clinically silent MRI lesions in relapsing-remitting multiple sclerosis.

Journal: Brain : a journal of neurology

Published: March 12, 2026

Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis.

Comparative Evaluation of Rituximab Versus Approved Therapies in Aquaporin-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder: A Systematic Review and Network Meta-analysis.

Journal: Neurology and therapy

Published: March 05, 2026

Neuromyelitis Optica Spectrum Disorders in Africa: A Systematic Review.

Neuromyelitis Optica Spectrum Disorders in Africa: A Systematic Review.

Journal: Neurology(R) neuroimmunology & neuroinflammation

Published: March 03, 2026

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study.

Journal: Journal of neurology, neurosurgery, and psychiatry

Published: January 13, 2026

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.

Journal: Journal of neurology

Published: November 01, 2025

Novel methods for the discovery of disease-associated T cell epitopes in autoimmunity.

Novel methods for the discovery of disease-associated T cell epitopes in autoimmunity.

Journal: Methods (San Diego, Calif.)

Published: October 13, 2025

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Stride-level measurement of gait as an early sensitive marker of disability progression in ambulatory patients with multiple sclerosis.

Journal: EClinicalMedicine

Published: September 26, 2025

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Predicting disease progression in multiple sclerosis with clinically accessible information and technology.

Journal: Journal of neurology

Published: September 16, 2025

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study.

Journal: CNS drugs

Published: September 04, 2025

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.

Real-world effectiveness of ocrelizumab in relapsing multiple sclerosis: An MSBase registry sub-study.

Journal: Multiple sclerosis and related disorders

Published: August 27, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026